We investigated the impact of dimethyl fumarate (DMF), an oral therapy for relapsing multiple sclerosis (MS), on blood microRNA (miRNA) signatures and neurofilament light (NFL) levels. DMF normalized miR-660-5p and modulated various miRNAs associated with the NF-kB pathway. These alterations reached a peak 4–7 months after treatment. Notably, particular miRNAs correlated with high or low NFL levels, implying their potential role as markers of treatment efficacy. Our findings broaden the understanding of DMF's immunomodulatory effects and may aid in predicting treatment responses.
Bibliografisk noteFunding Information:
The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article. MLE is grateful for financial support from Lundbeckfonden (R347-2020-2454). TS has received travel grants from Biogen, Merck, Novartis, and Roche, has received research grants from Biogen and Roche, has served on advisory boards for Biogen, Merck, Novartis and Roche. ZI is grateful for financial support from Biogen (DK-BGT-11542), from Scleroseforeningen (A25341, A29926, A31829, A33600), University of Southern Denmark (14/24200), Odense University Hospital (5798002573633).